Form 4: Clover Health Executive Sells Over 20,000 Shares Under Pre-Arranged Trading Plan

Jamie L. Reynoso, CEO of Medicare Advantage at Clover Health Investments, Corp., sold 20,450 shares of Class A Common Stock for a weighted average price of $2.86 per share, pursuant to a Rule 10b5-1 trading plan.

Summary

• Jamie L. Reynoso, the CEO of Medicare Advantage at Clover Health Investments, Corp. (CLOV), reported the sale of 20,450 shares of the company's Class A Common Stock.
• The transaction occurred on June 17, 2025, at a weighted average price of $2.86 per share.
• The shares were sold in multiple transactions with prices ranging from $2.82 to $2.92, inclusive.
• This sale was executed pursuant to a Rule 10b5-1 trading plan, which was adopted by Mr. Reynoso on March 13, 2025.
• Following this transaction, Mr. Reynoso beneficially owns 3,196,401 shares of Class A Common Stock directly.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to an executive selling a significant number of shares. While the 10b5-1 plan mitigates some of the immediate negative implications, insider selling is generally viewed with caution by investors.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, which indicates the transaction was scheduled in advance and not based on immediate, non-public information.

Negatives

• An executive selling a significant number of shares (20,450 shares) can be perceived negatively by investors, potentially signaling a lack of confidence in the company's near-term prospects.
• The sale occurred at a relatively low price point, with a weighted average of $2.86 per share.

Risks

• The sale by a key executive, even under a 10b5-1 plan, could lead to negative market sentiment and potentially put downward pressure on the stock price.
• Investor perception of insider selling may raise concerns about the company's future performance or valuation.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2025.
• The Reporting Person undertakes to provide full information regarding the number of shares sold at each separate price within the reported range upon request.

Industry Context

This Form 4 filing is specific to an insider transaction at Clover Health Investments, Corp. and does not provide broader industry context or trends within the healthcare or Medicare Advantage sectors.

Stakeholder Impact

• Shareholders may interpret the executive's sale as a bearish signal, potentially leading to decreased investor confidence and downward pressure on the stock price.

Key Dates

Keywords

Clover Health Investments, CLOV, Jamie L. Reynoso, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Executive Compensation, Healthcare, Medicare Advantage